Specialised equipment to store large numbers of chemical compounds as part of ongoing compound management rationalisation process
RTS Life Science International has signed a significant contract to supply AstraZeneca with specialised equipment to store and distribute very large numbers of chemical compounds either as solids or in solution.
This contract is part of a major global investment in state-of-the-art compound management technology taking place at AstraZeneca's Research sites in the UK, Sweden, and the USA.
RTS Life Science was chosen following an exhaustive design and tendering process.
Mike Cox, a member of AstraZeneca's global compound management venture team, explained: "Following the AstraZeneca merger we had an increase in both the number and diversity of compounds available for screening as potential new leads in the drug discovery process.
Our experience of working with RTS Life Science on smaller projects has given us confidence in its ability to deliver a cost effective solution within a given timeframe." The scale of research and development within AstraZeneca and its changed requirements now makes it opportune to build on the earlier investments of both former companies.
Accordingly, AstraZeneca has embarked on a three-year investment plan to rationalise its compound management activities, which are at the heart of its drug discovery process.
